NZ237176A - Insulin cobalt iii complex compositions - Google Patents

Insulin cobalt iii complex compositions

Info

Publication number
NZ237176A
NZ237176A NZ237176A NZ23717691A NZ237176A NZ 237176 A NZ237176 A NZ 237176A NZ 237176 A NZ237176 A NZ 237176A NZ 23717691 A NZ23717691 A NZ 23717691A NZ 237176 A NZ237176 A NZ 237176A
Authority
NZ
New Zealand
Prior art keywords
insulin
iii
ins
pharmaceutical composition
composition according
Prior art date
Application number
NZ237176A
Other languages
English (en)
Inventor
Jorgen Frederick Hansen
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NZ237176A publication Critical patent/NZ237176A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Chairs For Special Purposes, Such As Reclining Chairs (AREA)
NZ237176A 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions NZ237176A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK045590A DK45590D0 (enExample) 1990-02-21 1990-02-21

Publications (1)

Publication Number Publication Date
NZ237176A true NZ237176A (en) 1991-12-23

Family

ID=8093754

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ237176A NZ237176A (en) 1990-02-21 1991-02-20 Insulin cobalt iii complex compositions

Country Status (12)

Country Link
EP (1) EP0516704B1 (enExample)
JP (1) JPH05503940A (enExample)
AU (1) AU641991B2 (enExample)
CA (1) CA2075982A1 (enExample)
DE (1) DE69100626D1 (enExample)
DK (1) DK45590D0 (enExample)
HU (1) HUT63858A (enExample)
IE (1) IE910579A1 (enExample)
NZ (1) NZ237176A (enExample)
PT (1) PT96841A (enExample)
WO (1) WO1991012817A1 (enExample)
ZA (1) ZA911279B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
BR9407508A (pt) * 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
PT2275439E (pt) 2003-08-05 2014-06-25 Novo Nordisk As Novos derivados de insulina
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
ES2611007T3 (es) 2008-03-18 2017-05-04 Novo Nordisk A/S Análogos de insulina acilada, estabilizados frente a proteasas
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
EP3055325B1 (en) 2013-10-07 2018-01-03 Novo Nordisk A/S Novel derivative of an insulin analogue
DK3821905T3 (da) 2016-12-16 2022-11-14 Novo Nordisk As Insulin indeholdende farmaceutiske sammensætninger
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE971500C (de) * 1950-11-22 1959-02-05 Organon Nv Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung
DE1107374B (de) * 1958-01-31 1961-05-25 Organon Nv Verfahren zur Herstellung eines Insulin-Praeparates

Also Published As

Publication number Publication date
EP0516704B1 (en) 1993-11-10
DK45590D0 (enExample) 1990-02-21
HU9202721D0 (en) 1992-12-28
EP0516704A1 (en) 1992-12-09
ZA911279B (en) 1991-10-30
AU7337891A (en) 1991-09-18
HUT63858A (en) 1993-10-28
AU641991B2 (en) 1993-10-07
JPH05503940A (ja) 1993-06-24
IE910579A1 (en) 1991-08-28
PT96841A (pt) 1991-11-29
CA2075982A1 (en) 1991-08-22
WO1991012817A1 (en) 1991-09-05
DE69100626D1 (de) 1993-12-16

Similar Documents

Publication Publication Date Title
NZ237176A (en) Insulin cobalt iii complex compositions
US5266333A (en) Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
DE3880346T2 (de) Insulinderivate.
DE69425464T2 (de) Polysaccharidderivat und wirkstoffträger
DE69722397T2 (de) Insulin-derivate und ihre verwendung
KR890004687B1 (ko) 생물학적 활성 서방출성 조성물
DE69736780T2 (de) Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
DE69631824T2 (de) Biologisch abbaubare nanopartikel mit kontrollierter freigabe von insulin
DE69429169T2 (de) Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält
Zhang et al. Polymer–covalent organic frameworks composites for glucose and PH dual‐responsive insulin delivery in mice
EP3554534B1 (en) Insulin containing pharmaceutical compositions
EP0646379A1 (en) Insulin formulation
WO1995005848A1 (en) Protracted glp-1
JPH10511365A (ja) 遅延性glp−1組成物
EP2496213B1 (en) Pharmaceutical solution of non covalently bound albumin and acylated insulin
CN109069590A (zh) 包含聚山梨酯80的胰岛素制剂
EP0119650A2 (en) Galactosyl-insulin conjugates useful in treating diabetics
CA1335924C (en) Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus
CS114290A3 (en) Specifically glycosylated insulin derivatives
ZA200600846B (en) Novel insulin derivatives
Enriquez et al. Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity
CA2463769A1 (en) Composition and method for treating diabetes
KR20110014564A (ko) 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도
TW201934137A (zh) 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法